Adaptive Biotechnologies Corporation
Moat Score — Adaptive Biotechnologies Corporation
Total Moat Score
17 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Adaptive holds substantial patent protection around its immunoSEQ sequencing and bioinformatics platform, plus FDA clearances and established reimbursement for clonoSEQ that represent years of costly regulatory investment a new entrant cannot quickly replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Adaptive benefits from lab automation and scale in its central sequencing operations, but as a still-scaling diagnostics company it does not yet have a decisive unit-cost advantage over larger, more diversified diagnostics competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | clonoSEQ's unique clinical utility in blood-cancer MRD monitoring and its established Medicare/commercial reimbursement give Adaptive real pricing power within its niche, though payer negotiations still constrain how much of that value it can capture. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 3 / 5 | Adaptive's growing immune-repertoire database improves both diagnostic accuracy and drug-discovery capability as more samples are sequenced, creating a genuine data-driven flywheel that benefits both the clonoSEQ and Immune Medicine businesses. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Once oncologists build a treatment-monitoring protocol around clonoSEQ for a given patient, and once pharma partners have structured a multi-year collaboration around Adaptive's platform, both relationships carry real clinical and contractual switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The blood-cancer MRD testing niche is specialized enough that it does not support unlimited competitors at scale, but Adaptive still faces encroachment from larger, better-capitalized liquid biopsy companies expanding into adjacent indications. |